Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$4.48 USD

4.48
1,765,197

+0.05 (1.13%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $4.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Aurora Cannabis Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ACB stock based on the movements in the options market lately.

Sundeep Ganoria headshot

Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?

by Sundeep Ganoria

Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.

Sundeep Ganoria headshot

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

by Sundeep Ganoria

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Sundeep Ganoria headshot

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

Sundeep Ganoria headshot

Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of -36.36% and 1.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide (HITI) delivered earnings and revenue surprises of -50% and 0.22%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?

by Sundeep Ganoria

Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.

Sundeep Ganoria headshot

Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?

by Sundeep Ganoria

After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.

Sundeep Ganoria headshot

Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?

by Sundeep Ganoria

ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth (CGC) delivered earnings and revenue surprises of -840% and 9.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agilent Technologies (A) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Agilent (A) delivered earnings and revenue surprises of 3.97% and 2.64%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 2.53% and 1.08%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?

by Urmimala Biswas

ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.

Zacks Equity Research

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aurora Cannabis (ACB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and AdaptHealth Corp. (AHCO) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Predict a 25.67% Upside in Aurora Cannabis (ACB): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Aurora Cannabis (ACB) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Best Momentum Stocks to Buy for February 21st

by Zacks Equity Research

ACB, BHRB and BJ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 21, 2024.

Zacks Equity Research

New Strong Buy Stocks for February 21st

by Zacks Equity Research

BHRB, ACB, MWA, BJ and PRTH have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2024.

Zacks Equity Research

Best Value Stocks to Buy for February 21st

by Zacks Equity Research

ACB, and PRTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 21, 2024.

Zacks Equity Research

All You Need to Know About Aurora Cannabis (ACB) Rating Upgrade to Strong Buy

by Zacks Equity Research

Aurora Cannabis (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 50% and 9.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pre-Markets Soar after Trump Wins U.S. Presidential Election

by Zacks Equity Research

Pre-Markets Soar after Trump Wins U.S. Presidential Election

Mark Vickery headshot

Pre-Markets Surge on Historic Trump Victory

by Mark Vickery

The Dow is currently +1300 points, the S&P 500 +132, the Nasdaq +361 and the small-cap Russell 2000 +141 points.